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Background: Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor associated with gastric
carcinogenesis. 3,3'-Diindolylmethane (DIM) is a relatively non-toxic selective AhR modulator. This study was to
detect the effects of DIM on gastric cancer cell growth.
Methods: Gastric cancer cell SGC7901 was treated with DIM at different concentrations (0,10,20,30,40,50 μmol/L)
with or without an AhR antagonist, resveratrol. The expression of AhR and Cytochrome P4501A1 (CYP1A1), a classic
target gene of AhR pathway, were detected by RT-PCR and Western blot; cell viability was measured by MTT assay,
and the changes in cell cycle and apoptosis were analyzed by flow cytometry.
Results: RT-PCR and western-blot showed that with the increase of the concentration of DIM, AhR protein gradually
decreased and CYP1A1 expression increased, suggesting that DIM activated the AhR pathway and caused the
translocation of AhR from cytoplasm to nucleus. MTT assay indicated that the viability of SGC7901 cells was
significantly decreased in a concentration- and time-dependent manner after DIM treatment and this could be
partially reversed by resveratrol. Flow cytometry analysis showed that DIM arrested cell cycle in G1 phase and
induced cell apoptosis.
Conclusion: Selective aryl hydrocarbon receptor modulator 3,3'-Diindolylmethane inhibits SGC7901 cell proliferation
by inducing apoptosis and delaying cell cycle progression. AhR may be a potential therapeutic target for gastric
cancer treatment.
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Gastric cancer is one of the most common malignancy.
In the economically developping countries, gastric can-
cer is the second most frequntly diagnosed cancers and
the third leading cause of cancer death in males [1], the
overall 5-year survival rate is low (15% to 35%) because
of the high recurrence rates, nodal metastasis and the
short-lived response to chemotherapy [2]. In the present,
more and more studies focus on the molecular diagnosis
and therapy of gastric cancer [3].* Correspondence: chenminhu@vip.163.com
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reproduction in any medium, provided the orAryl hydrocarbon receptor (AhR) is a ligand-activated
transcription factor. After ligands such as polycyclic aro-
matic hydrocarbons (PAH) and halogenated hydrocarbons
(HAH) bind with AhR in cytoplasm, the ligand-AhR com-
plex is translocated to the nucleus and heterodimerizes
with the AhR nuclear translocator (ARNT). The complex
binds to the cognate enhancer sequence and subsequently
activates downstream gene expression [4].
Traditional studies of AhR function focused on its role
in regulating the expression of xenobiotic metabolizing
enzymes (XMEs) and mediating the xenobiotics metabo-
lism. Recent studies demonstrated that AhR may involve in
many important physiological and pathological processes
including individual development, cell differentiation,
and carcinogenesis [5]. AhR expression is upregulated in
lung [6], mammary gland [7], pancreatic [8] and gastricThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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improtant roles in regulating cellular proliferation, apo-
ptosis, cell cycle, migration and invasion [10]. As a pro-
tein related to cancer, AhR maybe a promising target
for cancer therapy. Our previous work found that an
AhR agonist, 2,3,7,8 –tetrachlorodibenzo -para-dioxin
(TCDD), inhibited gastric cancer cell growth [9]. But
TCDD itself is carcinogenic [11], So to find non-toxic or
low-toxic AhR modulators may be a new direction for
molecular-targeted therapy in gastric cancer.
Selective AhR receptor modulator 3,3'-Diindolylmethane
(DIM) is a class of relatively non-toxic indole derivatives.
DIM is an acid-catalyed consendation product of indole-
3-carbinol, a consititudent of cruciferous vegetables, and
is formed in the stomach [12]. DIM is an anti-cancer
agent, it suppresses cancer cell proliferation in mammary
[13], colon [14] and pancreatic [15] cancers.
There had been little reports about the effects of DIM
on gastric cancer cells growth, the present study was
designed to observe the effects of DIM on gastric cancer
cells growth and explore the possible mechanisms.
Methods
Cell line
Human gastric cancer cell line SGC7901 was obtained
from the Cancer Institute of Chinese Academy of Medical
Science. SGC7901 Cells were maintained in RPMI-1640
medium (GIBCO, Carlsbad, Calif, USA) supplemented
with 10% fetal bovine serum (Hyclone, USA), 1 × 105 U/L
of penicillin, and 0.1 g/L of gentamycin. The cellular
environment was maintained at 50 mL/L CO2 and 37°C.
Treatment of cells
DIM was purchased from Enzo Life Science company
(Bulter Pike plymouth meeting, PA, USA), resveratrol
and dimethyl sulfoxide (DMSO) were purchased from
Sigma Chemical Company (Bellefonte, PA, USA). DIM
and resveratrol were dissolved in DMSO. After incubat-
ing for 24 h, one group of cells was treated with DIM at
different concentrations (0, 10, 20, 30, 40, 50 μmol/L) for
24 hours. A second group was treated with DIM
(30 μmol/L) plus resveratrol (0, 1, 5, 10, 20 μmol/L) for
6 h. Another group was treated with DIM (30 μmol/L)
for different time intervals (0, 1, 6, 24, 48, 72 h), respect-
ively. Control cells received 1 mL/L DMSO only.
Reverse transcription-polymerase chain reaction (RT-PCR)
After harvesting the cell, total RNA was extracted using
the Qiagen RNeasy Mini Kit (Qiagen, Germany) accord-
ing to the manufacturer’s instructions. cDNA was
synthesized with 1 μg total RNA using reverse transcript-
ase, ReverTraAceTM (Toyobo Co., Osaka, Japan) under
the following conditions: 30°C for 10 min, 42°C for
20 min, 99°C for 5 min, and 4°C for 5 min. Polymerasechain reaction (PCR) was performed using 2 μl of com-
plementary DNA and 0.6 U Ex Taq DNA polymerase
(Takara, Dalian, China ) in 20 μl reaction system and for
30 cycle with 94°C denaturation for 30 s, 55°C annealing
for 30 s and 72°C elongation for 45 s.
The primer sequences were as follows: reverse tran-
scription–polymerase chain reaction (RT–PCR): AhR, 5’-
ACT CCA CTT CAG CCA CCA TC -3’ (forward) and
5’- ATG GGA CTC GGC ACA ATA AA -3’ (reverse), the
proposed size of PCR product was 204 bp. CYP1A1, 5’-
CCA TGT CGG CCA CGG AGT T -3’(forward) and 5’-
ACA GTG CCA GGT GCG GGT T -3’ (reverse), the pro-
posedsize of PCR product was 174 bp. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), 5’- GGG AAA CTG
TGG CGT GAT -3’(forward) and 5’- AAA GGT GGA
GGA GTG GGT -3’ (reverse), the prospected size of PCR
product was 309 bp. PCR products were subsequently
electrophoresed on a 1.5% agarose gel, and visualized
under a UV transilluminator.
Western blot analysis
Cells were lysed in buffer containing 20 mmol/L HEPES,
1 mmol/L EGTA, 50 mmol/L β-glycerophosphate,
2 mmol/L sodium orthovanadate, 100 mL/L glycerol,
10 mL/L Triton X-100, 1 mmol/L DTT, and 1× Protease
Inhibitor Cocktail (Roche, Mannheim, Germany). The
lysate was centrifuged at 13 000 g and 4°C for 10 min.
The supernatant was the total cell lysate. Protein concen-
tration was measured using the BCA protein assay kit
(Pierce Chemical Co., Rockford, IL, USA). Thirty micro-
grams of protein was loaded per lane, separated by
100 g/L SDS-PAGE, and transferred onto equilibrated
polyvinylidene difluoride membrane by electroblotting.
Membranes were blocked with 5% non-fat milk in 1%
TBS-T buffer for 2 h at room temperature. AhR,
CYP1A1, and GAPDH were detected for 2 h using anti-
bodies against AhR (SC-5579, Santa Cruz Biotechnology,
USA, working dilution 1:150), CYP1A1 (AB1258, Chemi-
con International, USA, working dilution 1:500), and
GAPDH (2118, Cell Signaling Technology, USA, working
dilution 1:1000). After secondary antibody incubation
(7074,Cell Signaling Technology, USA, working dilution
1:2000) for 2 h, protein bands were detected using ECL
system (Pierce Biotechnology, Inc., USA).
Cell viability assay
The effect of DIM on the proliferation of gastric cancer
cells was determined by MTT assay. Briefly, A total of
1 × 104 trypsin-dispersed cells in 0.1 mL culture medium
were seeded into each well of a 96-well plate and cul-
tured for 24 hours. Next, cells were treated with DIM as
described above. Then, 20 μL of MTT (5 g/L) was added
to each well and the incubation was continued for 4 h
at 37°C. Finally, the culture medium was removed and
Figure 1 AhR and CYP1A1 expression in SGC7901 cells after DIM treatment. A and B: RT-PCR; C and D: Western blotting. Treatment of
SGC7901 cells with AhR modulator DIM resulted in a time - (A and C) and concentration -dependent (B and D) induction of CYP1A1 expression.
The results shown are representative of three independent experiments.
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bance was determined with an ELISA reader at 490 nm.
The cell viability percentage was calculated as: Viability
percentage (%) = (Absorption value of experiment group)/
(Absorption value of control group)× 100%.Flow cytometric analysis
SGC7901 cells were plated on 60-mm diameter culture
plates and treated with DIM at different concentration
(10, 20, 30, 40, 50 μmol/L) for 48 h. The control con-
tained 1 mL/L DMSO only. Prior to harvesting, the cells
were washed twice with 0.01 mol/L PBS, trypsinized, and
pelleted. The cells were then fixed with 70% ice-cold
ethanol at 4°C overnight. Finally, the cells were washed
twice with PBS and dyed with PI. The DNA content was
analyzed with a flow cytometer (Beckman-Coulter, Brea,
USA). The cell cycle of SGC7901 cells were analyzed
using MULTYCYCLE and winMDI2.9 software (Phoenix,
AZ, USA). For cell apoptosis analysis, after incubation
for 48 h, cells were stained with annexin V-FITC and PI.
Cells with annexin V (−) and PI (−) were deemed viable
cells. Cells with annexin V (+) and PI (−) were deemed
early apoptotic cells. Cells with both annexin V (+) and
PI (+) were deemed late apoptotic cells.Figure 2 Inhibition of DIM -induced CYP1A1 mRNA and
protein expression by resveratrol. A: CYP1A1 mRNA was detected
by RT-PCR; B: CYP1A1 protein was detected by Western blotting.
RSV: resveratrol . The results shown are representative of three
independent experiments. Treatment of SGC7901 cells with
30 μmol/L DIM caused a remarkable increase in CYP1A1 expression.
This DIM-induced CYP1A1 expression was partially reversed by
resveratrol in a concentration-dependent manner.Statistical analysis
All quantitative data were expressed as mean± SD and
analyzed using a one-way analysis of variance (ANOVA).
All statistical analyses were carried out using the SPSS sta-
tistical software package (version 11.0, SPSS Inc. Chicago,
USA). P< 0.05 was considered statistically significant.Results
Activation of AhR pathway by DIM
To test whether the AhR signal pathway could be acti-
vated by DIM, we treated the gastric cancer cell line
SGC7901 with DIM. RT-PCR and Western blot analysis
showed that after DIM treatment, AhR protein in the
total cell lysates gradually decreased (Figure 1). CYP1A1,
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of AhR signal pathway activation. The baseline level of
CYP1A1 expression was not observed in SGC7901 cells,
but both CYP1A1 mRNA and protein expression were
increased in a dose- and time-dependent manner follow-
ing DIM treatment (Figure 1). To further confirm the
DIM-induced CYP1A1 expression was AhR-dependent,
we treated SGC7901 cells with a specific AhR antagonist,
resveratrol [16,17]. cells were treated with DIM (30 μmol/L)
only or DIM (30 μmol/L) plus different concentrations of
resveratrol (0, 1, 5, 10, 20 μmol/L), respectively for 6 h
(Figure 2). In concordance with previous results, treat-
ment of SGC7901 cells with 30 μmol/L DIM caused aFigure 3 Viability of SGC7901 cells after DIM treatment was assessed
a concentration- and time-dependent manner after DIM treatment. Resver
(30 μmol/L) on cellur proliferation.remarkable increase in CYP1A1 expression. However, this
DIM-induced CYP1A1 expression was partially reversed
by resveratrol in a dose-dependent manner (Figure 2A
and B).
Effect of DIM on cellur proliferation
Proliferation of SGC7901 cells was determined by MTT
assay after 6–72 h of treatment with increasing con-
centrations of DIM (0–50 μmol/L). Results showed
that DIM inhibited SGC7901 cellular proliferation in a
concentration- and time-dependent manner, Resveratrol
(10 μmol/L) could partially reverse the inhibition effects
of DIM (30 μmol/L) on cellur proliferation at the timeby MTT assay. Viability of SGC7901 cells was significantly decreased in
atrol(10 μmol/L) could partially reverse the inhibition effects of DIM
Figure 4 The effect of DIM on cell cycle of SGC7901 cells. SGC7901 cells were treated with different concentrations of DIM and
subjected to flow cytometric analysis. The percentage of each phase is indicated in each panel. The results shown are representative of three
independent experiments.
Yin et al. Journal of Experimental & Clinical Cancer Research 2012, 31:46 Page 5 of 9
http://www.jeccr.com/content/31/1/46
Yin et al. Journal of Experimental & Clinical Cancer Research 2012, 31:46 Page 6 of 9
http://www.jeccr.com/content/31/1/46points: 6 h and 12 h (Figure 3), but we did not find the
reversal effects at other time points (24 h, 48 h and
72 h, data were not shown).
Effect of DIM on cell cycle
Flow cytometric analysis revealed that DIM treatment
induced changes in cell cycle distribution, with increased
accumulation of SGC7901 cells in the G1 phase and
compensation for this change by a decrease of cells in
the S phase (Figure 4 and Table 1).
Effect of DIM on cell apoptosis
48 h after DIM treatment, the changes of cell apoptosis
were observed by flow cytometric analysis. Compared to
the control group, cell apoptosis was induced at concen-
trations of 20 to 50 μmol/L, and the apoptosis rate
increased in a dose-dependent manner. These results
showed that DIM could induce cell apoptosis in SGC7901
cells (Figure 5 and Table 2).
Discussion
Our previous work found that the expression of AhR
was significantly up-regulated in gastric cancer, and may
be involved in the early stage of gastric carcinogenesis,
regulation of the AhR pathway may have a potential role
in the treatment of gastric cancer. We hypothesized that
AhR ligands may be utilized for gastric cancer therapy.
Then our futher studies showed that TCDD, a potent
AhR agonist, could supresse the growth of gastric cancer
cell AGS in a dose- and time-depengent manner via
induction of growth arrest at the G1-S phase [9]. But
TCDD itself is carcinogenic, it induces a broad spectrum
of biological responses, including induction of CYP1A1,
disruption of normal hormone signaling pathways, repro-
ductive and developmental defects, immunotoxicity, liver
damage, wasting syndrome, and cancer [18], so non-toxic
or low-toxic selective AhR modulators maybe served as
possible agents for gastric cancer.
From the studies in breast cancer, Safe found two




Percentage of cell cycle (%)
G1 G2 S
0 55.90 ± 1.48 10.5 ± 0.95 33.63 ± 0.55
10 57.20 ± 0.36* 9.10 ± 0.3 33.70 ± 0.53
20 61.03 ±1.53* 8.17 ± 0.68 30.77 ± 0.97*
30 61.97 ± 0.32* 9.83 ± 0.32 28.23 ± 0.60*
40 62.77 ± 1.46* 9.13 ± 0.91 28.10 ± 0.56*
50 73.03 ± 4.05* 9.17 ± 1.51 18.07 ± 0.57*
*p< 0.05, vs the control.(1,3,6,8- and 2,4,6,8-) alkyl polychlorinated dibenzofurans
(PCDFs) and substituted diindolylmethanes (DIMs), com-
pared to TCDD, these compounds are relatively non-toxic
and inhibit ER-positive and ER-negative mammary tumor
growth, but do not induce AhR-mediated toxic responses
induced by TCDD [19].
DIM represents a new class of relatively non-toxic
antitumorigenic AhR modulators which are of phyto-
chemical origin. Compared to TCDD, DIM is a weak
agonist of AhR for induction of CYP1A1 gene expression
[20] and activities [21], and it shows abilities to compete
for binding of TCDD to the AhR [22].
To test wether the AhR signal pathway could be acti-
vited by DIM in gastric cancer cells, we treated gastric
cancer cell line SGC7901 with DIM. Results showed that
AhR protein in the total cell lysates gradually decreased
(Figure 4C and D), Similar phenomena have been
reported by our labs and several other groups [9,23],
the down-regulation of AhR following ligand binding is
regarded as an imprtant step of AhR signal pathway [23].
CYP1A1, a classic target gene of AhR, was chosen as an
indicator of AhR signal pathway activation. Baseline levels
of CYP1A1 expression were not observed in SGC7901
cells in the present study. However, expression of CYP1A1
was significantly increased in a concentration- and time-
dependent manner after DIM treatment, indicating the
activation of AhR. To confirm the activation of the AhR
signal pathway by DIM, we treated SGC7901 cells with a
specific AhR antagonist, resveratrol. Our results showed
that DIM -induced CYP1A1 expression was partially
reversed by resveratrol in a concentration-dependent man-
ner. The incomplete reversal of CYP1A1 expression by
resveratrol may be due to the fact that AhR is not the only
regulator of CYP1A1 transcription [24]. Taken together,
these results suggest that DIM could activate the AhR
signal pathway in gastric cancer cells.
MTT assay demonstrated that the viability of SGC7901
cells was significantly decreased in a concentration- and
time-dependent manner after DIM treatment. To fur-
ther clarify wether this effects was AhR- dependent,
we treated SGC7901 cells with DIM and resveratrol,
we found that the inhibition effects of DIM on SGC7901
cells growth was partially but not completely reserved by
reservatrol, suggesting that DIM inhibits gastric cancer
cell growth partially via AhR pathway. This result is in
accordance with previous studies: Hong,C found that
DIM inhibited growth of both Ah-responsive and Ah-
non-responsive breast cancer cells. some of the anti-
carcinogenic activities of DIM are AhR –independent
[25]. Interestingly, the reversal effect on cell proliferation
was observed after cells were treated with DIM plus
reservatrol for 6 h or 12 h, but not at longer time points
(24 h, 48 h and 72 h), this maybe related to the time-
effectiveness of reservatrol.
Figure 5 The effect of DIM on apoptosis of SGC7901 cells. SGC7901 cells were treated with different concentrations of DIM and subjected to
flow cytometric analysis. The results shown are representative of three independent experiments.
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machanisms of DIM. Choi HJ showed that DIM induced
G1 and G2/M phase cell cycle arrest in HT-29 human
colon cancer cells [26]. Vivar OI and Hong C found
DIM induced a G(1) arrest in human prostate cancer
cells [27] and human breast cancer cells [28]. On theother hand, some articles reported that DIM may pro-
mote apoptosis in cancer cells by survivin , uPA and
uPAR or NF-kappaB sinaling [29-33].
To further explore the specific mechanisms of gastric
cancer cell growth inhibition by DIM, we treated
SGC7901 cells with DIM, then tested the changes of cell
Table 2 The effect of DIM on apoptosis of SGC7901 cells
DIM concentration (μmol/L) Apoptosis rate (%)
0 4.18 ± 0.23
10 4.81 ± 0.42
20 6.07 ± 0.33*
30 7.23 ± 0.78#
40 7.39 ± 1.08#
50 9.14 ± 0.32#
*p< 0.05, #p< 0.01vs the control.
Yin et al. Journal of Experimental & Clinical Cancer Research 2012, 31:46 Page 8 of 9
http://www.jeccr.com/content/31/1/46cycle and cell apoptosis by flow cytometric analysis.
The results showed that with the increase of DIM con-
centration, cells in G1 phase gradually increased, cells
in S phase decreased, but cells in G2 phase remained un-
changed, indicating that DIM could arrest cell cycle in
G1 phase. Different from TCDD, DIM also induced cell
apoptosis, suggesting that DIM could suppress
gastric cancer cell proliferation through inducing apo-
ptosis and arresting cell cycle, However, the mechanisms
responsible for the effects of DIM on gastric cancer
cell cycle and apoptosis are still needed to be fur-
ther studied.
Conclusions
In surmary, this report showed that non-toxic selective
AhR modulator DIM inhibited the proliferation of human
gastric cancer cell line SGC7901 in vitro by inducing cell
apoptosis and arresting cell cycle at G1 phase. Our find-
ings suggested that AhR might be a promising target for
gastric cancer treatment.
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